Puritanism pays

3 Feb 2021 By Robert Cyran

It was a long slog for GW Pharmaceuticals to win official approval for an epilepsy drug derived from cannabis. This difficulty is now a moat, and has attracted a buyer willing to pay a 50% premium. Rivals will have to jump the same regulation hoops to earn a similar valuation.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)